Cancer Biomarker Global Market Report 2025

Description

A cancer biomarker is a biological molecule found in blood, tissues, or other bodily fluids that serves as an indicator of normal or abnormal activity and the presence of a specific condition or disease, particularly cancer. These biomarkers are crucial in characterizing alterations within tumors.

The primary types of cancer biomarkers include protein biomarkers, genetic biomarkers, and those utilizing omics technologies, imaging technologies, immunoassay, bioinformatics, and cytogenetics profiling technologies. Protein biomarkers are identifiable markers in a patient's blood that correlate with significant events or signal distinct states in a biological process, such as disease progression. They are employed for accurate disease diagnosis. Cancer biomarkers find applications in various cancer types, including breast cancer, lung cancer, colorectal cancer, prostate cancer, thyroid cancer, kidney cancer, and others. These biomarkers are utilized in diagnostics, research and development, prognostics, risk assessment, and various other applications.

The cancer biomarkers market research report is one of a series of new reports from The Business Research Company that provides cancer biomarkers market statistics, including cancer biomarkers industry global market size, regional shares, competitors with a cancer biomarkers market share, detailed cancer biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biomarkers industry. This cancer biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer biomarker market size has grown rapidly in recent years. It will grow from $22.19 billion in 2024 to $25.28 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to shift to personalized medicine, immunotherapy innovations, regulatory framework evolution, collaborative research efforts, focus on non-coding RNAs.

The cancer biomarker market size is expected to see rapid growth in the next few years. It will grow to $45.88 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to shift to patient-centric diagnostics, integration of biomarkers in clinical trials, emergence of multiplex biomarker panels, exploration of non-coding RNAs, commercialization of biomarker tests. Major trends in the forecast period include advancements in genomics, precision medicine approaches, liquid biopsies, immunotherapy advancements, artificial intelligence (ai) integration.

The cancer biomarker market is experiencing substantial growth driven by the increasing incidence of cancer. The rise in cancer incidence rates, measured as the number of new cancers per 100,000 people at risk, has led to a widespread use of cancer biomarkers. These biomarkers play a crucial role in assessing disease risk, screening for occult primary tumors, distinguishing between benign and malignant signs, and categorizing different forms of malignancy. Notably, in January 2022, the American Cancer Society reported an anticipated 1.9 million new cancer cases and 609,360 cancer deaths in the US for 2022. With cancer claiming approximately 1,670 lives each day, the escalating incidence of cancer is expected to drive the growth of the cancer biomarker market in the foreseeable future.

The growth of the cancer biomarker market is further propelled by the increase in the geriatric population. As the percentage of people aged 65 and older rises globally, there is a heightened risk of cancer development among the aging population. This surge in risk amplifies the demand for cancer biomarkers, emphasizing the need for early detection, personalized treatment, and targeted interventions. According to a report by the World Health Organization (WHO) in October 2022, one in six people is projected to be 60 or older by 2030, with the global population of individuals aged 60 years and older expected to reach 2.1 billion by 2050. The increase in the geriatric population is a significant driver for the growth of the cancer biomarker market.

Leading companies in the cancer biomarker market are focusing on developing cutting-edge solutions, such as AI-powered cancer biomarkers, to improve diagnostic precision and tailor treatment plans for patients. AI-powered cancer biomarkers are biological indicators of cancer that are identified and analyzed using advanced artificial intelligence technologies. For example, in September 2023, Ibex Medical Analytics, a US-based company, introduced Galen Breast HER2, an AI-powered solution aimed at improving the accuracy and consistency of HER2 scoring in breast cancer patients. This innovative platform assists pathologists by automatically detecting invasive tumor regions and quantifying HER2 expression in accordance with the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system uses a novel computational process to analyze immunohistochemistry (IHC)-stained slides, offering detailed visual representations of staining patterns and helping pathologists make more informed treatment decisions.

Innovation in products, specifically AI-powered cancer diagnostics solutions, is a key focus for major companies in the cancer biomarker market. AI-powered cancer diagnostics leverage advanced computational methods to analyze medical data and aid in the detection, diagnosis, and characterization of cancer. In September 2023, Ibex Medical Analytics launched Galen Breast HER2, an AI-powered solution for HER2 IHC scoring in breast cancer. This solution automates the detection of invasive tumor areas, identifies tumor cells, and calculates the HER2 IHC score with exceptional accuracy. It supports pathologists in achieving precise and consistent HER2 scoring in breast cancer patients.

In November 2022, Biocare Medical, a California-based company specializing in the development and supply of automated immunohistochemistry (IHC) solutions, acquired Empire Genomics for an undisclosed amount. This acquisition is intended to bolster Biocare Medical's cancer diagnostics capabilities by incorporating a broader range of molecular biomarkers and custom genomic development solutions. Empire Genomics, a U.S.-based biotechnology firm, develops and provides molecular diagnostics and genomic products, including cancer biomarkers, enhancing diagnostic precision and personalized treatment options in oncology.

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMerieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

North America was the largest region in the cancer biomarker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cancer biomarker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cancer biomarker market consists of sales of epigenetic biomarkers, and metabolic biomarkers for various cancers such as melanoma, leukemia, bladder cancer, non-hodgkin's lymphoma, endometrial cancer, pancreatic cancer, and liver cancer. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Biomarker Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer biomarker market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer biomarker ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer biomarker market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Biomarkers Type: Protein Biomarkers; Genetic Biomarkers; Other Cancer Biomarkers
2) By Profiling Technologies: Omics Technologies; Imaging Technologies; Immunoassay; Bioinformatics; Cytogenetics
3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Thyroid Cancer; Kidney Cancer; Other Cancers
4) By Application: Diagnostics; Research And Development; Prognostics; Risk Assessment; Other Applications
Subsegments:
1) By Protein Biomarkers: Tumor-Specific Antigens; Circulating Tumor Protein
2) By Genetic Biomarkers: DNA Mutations; RNA Expression Profiles
3) By Other Cancer Biomarkers: Epigenetic Biomarkers; Metabolomic Biomarkers
Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; QIAGEN NV; Illumina Inc.; Bio-Rad Laboratories Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r22446

1. Executive Summary

2. Cancer Biomarker Market Characteristics

3. Cancer Biomarker Market Trends And Strategies

4. Cancer Biomarker Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cancer Biomarker Growth Analysis And Strategic Analysis Framework

5.1. Global Cancer Biomarker PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Cancer Biomarker Market Growth Rate Analysis
5.4. Global Cancer Biomarker Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Cancer Biomarker Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Cancer Biomarker Total Addressable Market (TAM)

6. Cancer Biomarker Market Segmentation

6.1. Global Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Protein Biomarkers
Genetic Biomarkers
Other Cancer Biomarkers
6.2. Global Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Omics Technologies
Imaging Technologies
Immunoassay
Bioinformatics
Cytogenetics
6.3. Global Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Thyroid Cancer
Kidney Cancer
Other Cancers
6.4. Global Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diagnostics
Research And Development
Prognostics
Risk Assessment
Other Applications
6.5. Global Cancer Biomarker Market, Sub-Segmentation Of Protein Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tumor-Specific Antigens
Circulating Tumor Protein
6.6. Global Cancer Biomarker Market, Sub-Segmentation Of Genetic Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
DNA Mutations
RNA Expression Profiles
6.7. Global Cancer Biomarker Market, Sub-Segmentation Of Other Cancer Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Epigenetic Biomarkers
Metabolomic Biomarkers

7. Cancer Biomarker Market Regional And Country Analysis

7.1. Global Cancer Biomarker Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Cancer Biomarker Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Biomarker Market

8.1. Asia-Pacific Cancer Biomarker Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Biomarker Market

9.1. China Cancer Biomarker Market Overview
9.2. China Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Biomarker Market

10.1. India Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Biomarker Market

11.1. Japan Cancer Biomarker Market Overview
11.2. Japan Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Biomarker Market

12.1. Australia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Biomarker Market

13.1. Indonesia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Biomarker Market

14.1. South Korea Cancer Biomarker Market Overview
14.2. South Korea Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Biomarker Market

15.1. Western Europe Cancer Biomarker Market Overview
15.2. Western Europe Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Biomarker Market

16.1. UK Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Biomarker Market

17.1. Germany Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Biomarker Market

18.1. France Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Biomarker Market

19.1. Italy Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Biomarker Market

20.1. Spain Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Biomarker Market

21.1. Eastern Europe Cancer Biomarker Market Overview
21.2. Eastern Europe Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Biomarker Market

22.1. Russia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Biomarker Market

23.1. North America Cancer Biomarker Market Overview
23.2. North America Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Biomarker Market

24.1. USA Cancer Biomarker Market Overview
24.2. USA Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Biomarker Market

25.1. Canada Cancer Biomarker Market Overview
25.2. Canada Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Biomarker Market

26.1. South America Cancer Biomarker Market Overview
26.2. South America Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Biomarker Market

27.1. Brazil Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Biomarker Market

28.1. Middle East Cancer Biomarker Market Overview
28.2. Middle East Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Biomarker Market

29.1. Africa Cancer Biomarker Market Overview
29.2. Africa Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Biomarker Market Competitive Landscape And Company Profiles

30.1. Cancer Biomarker Market Competitive Landscape
30.2. Cancer Biomarker Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. QIAGEN NV Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Biomarker Market Other Major And Innovative Companies

31.1. Abbott Laboratories
31.2. bioMerieux SA
31.3. Becton Dickinson and Company
31.4. Merck & Co. Inc.
31.5. Bristol-Myers Squibb Company
31.6. PerkinElmer Inc.
31.7. Siemens AG
31.8. Exact Sciences Corporation
31.9. Novartis AG
31.10. Agilent Technologies Inc.
31.11. Hologic Inc.
31.12. Myriad Genetics Inc.
31.13. Foundation Medicine Inc.
31.14. Guardant Health Inc.
31.15. Natera Inc.

32. Global Cancer Biomarker Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Biomarker Market

34. Recent Developments In The Cancer Biomarker Market

35. Cancer Biomarker Market High Potential Countries, Segments and Strategies

35.1 Cancer Biomarker Market In 2029 - Countries Offering Most New Opportunities
35.2 Cancer Biomarker Market In 2029 - Segments Offering Most New Opportunities
35.3 Cancer Biomarker Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer